Translational Drug Development (TD2)
Maggie Valenzuela Murray has extensive experience in nonclinical operations and project management in the pharmaceutical industry. Maggie began their career at Pharmatek Laboratories, Inc. in 2005 as a Pharmaceutical Chemist. From 2009 to 2013, they worked at TGen as a Project Manager in nonclinical operations. Maggie then joined Translational Drug Development (TD2) in 2013 as an Assistant Director and later became the Director of Nonclinical Operations in April 2020.
Maggie Valenzuela Murray graduated from the University of San Diego in 2005 with a Bachelor's degree. During their time at the university, they pursued a diverse academic path, studying Biology, Chemistry, and Political Science.
This person is not in any teams
Translational Drug Development (TD2)
Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases. We help companies move their drugs through the critical stages of preclinical, regulatory and clinical trial processes. Our scientific depth, proactive problem solving, and strategic direction and advice increase the likelihood of positive outcomes that bring hope and a better quality of life to cancer patients and their families. TD2 was born from the Translational Genomics Research Institute (TGen) as a nonprofit in 2003. TGen’s deep scientific expertise and approach to interrogating the “omic” drivers of disease is at the heart of TD2’s heritage and has become the foundation upon which TD2 creates unique clinical strategies for its clients.